Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773018 | 0.78 | CYP1A2 (0.42) | LRRK2CYP3A4CYP2D6 | |
| SCHEMBL3775019 | 0.77 | UTS2R (0.55) | LRRK2UTS2RALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL3764126 | 0.76 | GAA (0.38) | LRRK2ALDH1A1MAPT | |
| SCHEMBL13006154 | 0.76 | ALDH1A1 (0.39) | TLR8TLR7ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3775684 | 0.76 | TLR8 (0.45) | TLR8TLR7LRRK2UTS2RCYP3A4 | |
| SCHEMBL3805720 | 0.76 | MAPK1 (0.52) | ALDH1A1MAPTSMN1; SMN2CASP1CASP7 | |
| SCHEMBL3766765 | 0.75 | LRRK2 (0.40) | LRRK2UTS2RALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL3766209 | 0.75 | JAK2 (0.41) | CYP3A4 | |
| SCHEMBL3772245 | 0.74 | KIT (0.42) | LRRK2UTS2RALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL3768544 | 0.74 | UTS2R (0.57) | LRRK2UTS2RCYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | TLR8 1090/4885TLR7 173/4885LRRK2 2309/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | TLR8 1057/4885TLR7 177/4885LRRK2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.